Genetic Testing Global Market Report 2023 – By Type (Predictive Testing Carrier Testing Prenatal and Newborn Testing Diagnostic Testing Pharmacogenomic Testing Nutrigenomic Testing Other Types), By Technology (Cytogenetic Testing Biochemical Testing Molecular Testing), By Disease (Alzheimers Disease Cancer Cystic Fibrosis Sickle Cell Anemia Duchenne Muscular Dystrophy Thalassemia Other Diseases), By Application (Cancer Diagnosis Genetic Disease Diagnosis Cardiovascular Disease Diagnosis Other Applications) – Market Size, Trends, And Global Forecast 2023-2032

COVID-19 Rapid Test Kits Market Definition

The COVID-19 rapid test kits market consists of sales of COVID-19 rapid test kits and related services by entities (organizations, sole traders and partnerships) that offer kits aimed at the detection of COVID-19. COVID-19 rapid test kits are usually available as RT PCR test kits, rapid antigen test kits, or rapid antibody test kits and are manufactured by the entities that manufacture in-vitro rapid diagnostic tests in the medical equipment industry. The companies involved in manufacturing these rapid test kits are primarily engaged in the design, research and production of the rapid test kits which are used in hospitals and clinics, home care, diagnostic laboratories, and research institutions. COVID-19 is an infectious disease caused by the most recently discovered coronavirus. The most commonly used COVID-19 rapid tests are RT PCR and TrueNat PCR tests, which are primarily based on PCR, a procedure that repeatedly copies and amplifies the specific genetic fragments of the virus for detection. Other COVID-19 rapid test kits are an immunochromatography test designed for the qualitative presumptive detection of specific Immunoglobulin M (IgM) and Immunoglobulin G (IgG) to SARS-CoV-2 in humoral fluid. These types of test kits require whole blood, serum, plasma, nasopharyngeal swab, oropharyngeal swab, or nasal swab as a sample to detect COVID-19 in humans; and are also suitable for point of care testing.

Point-of-care diagnostics devices are designed to aid doctors in performing medical diagnostic testing at or near the point of care, for immediate knowledge on diseases or conditions. These devices are used to test glucose and cholesterol levels, do electrolyte and enzyme analysis, test for drugs of abuse and for infectious diseases, and for pregnancy testing. The main types of point-of-care diagnostic devices and equipment are infectious disease testing kits, cardiometabolic monitoring kits, cholesterol testing kits, pregnancy and fertility tests kits, tumor/cancer markers, urinalysis testing kits, hematology testing kits, drugs of abuse testing kits, fecal occult testing kits, and others. Pregnancy and fertility test kits are point-of-care diagnostic devices used to test pregnancy and fertility prior to seeing a doctor. The various prescription modes include prescription-based testing devices, and over-the-counter (OTC) testing devices. These are used by end-users such as professional diagnostic centers, hospitals/critical care centres, outpatient healthcare settings, ambulatory care settings, research laboratories, and homes. The global point-of-care diagnostics devices and equipment market is segmented - 1) By Type: Infectious disease testing kits, Cardio metabolic monitoring kits,, Cholesterol testing kits, Pregnancy and fertility tests kits, Tumor/Cancer markers, Urinalysis testing kits, Hematology testing kits, Drugs of abuse testing kits, Fecal occult testing kits, Other Types 2) By End User: Professional diagnostic centers, Hospitals/critical care centers, Outpatient healthcare Setting, Ambulatory care settings, Research laboratories, Home 3) By Prescription Mode: Prescription-based Testing Devices, Over-The-Counter (OTC) Testing Devices The global point-of-care diagnostics devices and equipment market size will grow from $28.47 billion in 2022 to $32.34 billion in 2023 at a compound annual growth rate (CAGR) of 13.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global point-of-care diagnostics devices and equipment is expected to grow to $48.35 billion in 2027 at a CAGR of 10.6%. An increase in the incidence of target diseases is driving the POC devices and equipment market globally. The rising incidence of chronic diseases, like diabetes, rheumatism, or cancer is increasing steadily worldwide due to poor lifestyle choices and increasing obesity, thus driving the growth of the POC devices and equipment market. For example, according to the Centers for Disease Control and Prevention, In 2020, about 697,000 people in the US died due to heart disease. Major players in the point-of-care diagnostic devices and equipment market report are Abbott, F. Hoffmann-La Roche, Siemens Healthineers, Danaher, Beckman Coulter, Becton Dickinson and Company, QIAGEN N.V., Johnson & Johnson, Alere Inc., and BioMerieux. The POC diagnostics devices and equipment market is expected to slow down due to stringent regulatory policies, which increase the gestational period before the product enters the market. POC devices and equipment manufacturers are required to obtain multiple FDA clearances before launching their product into the market. The entire process of approval consumes a lot of time, thereby restraining the point-of-care diagnostic devices and equipment market growth. Over-the-Counter (OTC) testing is being termed as an important trend driving the growth of the point of care diagnostics market. FDA has approved OTC test kits for cholesterol, fecal occult blood, pregnancy, and HIV/HCV. This method would improve the access to testing and early detection of the disease. These testing kits may generate more revenue than prescription tests over the forecast period due to ease of using the kits, increased home care and self-testing, and a rise in availability and adoption rate. Point of care devices is regulated by the U.S. Food and Drug Administration (FDA) and all the diagnostic laboratory tests are regulated by the clinical laboratory improvement amendments of 1988 (CLIA) that are administered by the Centers for Medicare & Medicaid Services (CMS). As these devices measure the biomarker levels in the body they are classified as class II (requiring 510[k] approval), or III devices (requiring the more tedious premarket approval). On the contrary, to the stringent approvals by FDA, China has a moderately lenient approval mechanism. Therefore, the top companies are using a partnership approach with local vendors and distributors to expand their point-of-care diagnostic devices and equipment market share. North America was the largest region in the point-of-care diagnostic devices and equipment market in 2022. Asia-Pacific was the second-largest region in the global point-of-care diagnostics devices and equipment market share. The regions covered in point-of-care diagnostics devices and equipment market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the point-of-care diagnostic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and USA. The point-of-care diagnostics market consists of sales of instruments such as pregnancy and fertility testing kits, cholesterol test strips, drug abuse testing kits, and others that are used in point-of-care diagnostics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The point-of-care diagnostics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides point-of-care diagnostics devices and equipment market statistics, including point-of-care diagnostics devices and equipment industry global market size, regional shares, competitors with a point-of-care diagnostics devices and equipment market share, detailed point-of-care diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care diagnostics devices and equipment industry. This point-of-care diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hospital-acquired infection testing kits are tools used to check the infections people get while in a healthcare facility. Hospital-acquired infections testing kits are used to check the infections associated with pathogens such as vancomycin-resistant enterococci (VRE), methicillin-resistant staphylococcus aureus (MRSA), multi-resistant gram-negative bacilli, norovirus, and Clostridium difficile. The main products of hospital-acquired infection testing kits are instruments, reagents, and consumables. The hospital-acquired infections testing kit instruments involve the various instruments that are required for hospital-acquired infections testing to aid scientists in growing new cells in the culture media for drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. Pathogens tested using hospital-acquired infections testing kits include viral, bacterial, and fungal pathogens using sterilization, chemical, and radiation methods of treatment to test for pneumonia infection, urinary tract infection, bloodstream infection, surgical site infection, MRSA infection, and others.The various applications include drug-resistance testing and disease testing. The global hospital acquired infections testing kits market is segmented - 1) By Product: Instrument & Reagents, Consumables 2) By Test Type: Pneumonia Infection, Urinary Tract Infection, Blood Stream Associated Infection, Surgical Site Infection, MRSA Infection, Other Test Types 3) By Application: Drug-resistance Testing, Disease Testing 4) By Pathogen Type: Viral, Bacterial, Fungal 5) By Method of Treatment: Sterilization, Chemical, Radiation The global hospital acquired infections testing kits market size grew from $1.27 billion in 2022 to $1.4 billion in 2023 at a compound annual growth rate (CAGR) of 10.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global hospital acquired infections testing kits is expected to grow from $2 billion in 2027 at a CAGR of 9.4%. The hospital-acquired infections (HAIs) are on the rise, affecting both the inpatients and outpatients. Hospital-acquired infections or nosocomial infections are diseases that are acquired in hospitals and medical clinics. For example, according to the findings by the Center for Disease Control and Prevention, around 1.7 million people in the USA acquire hospital-acquired infections caused while being admitted for other health issues and more than 98,000 (around 5%) patients die due to these infections. The increasing incidence of hospital-acquired infections leads to an increase in the demand for hospital-acquired infections testing kits market. Major players in the hospital-acquired infections testing kits market are Becton, Dickinson and Company, Abott Laboratories, Cepheid, F. Hoffmann-La Roche Ltd., Hologic, Roche, Bayer AG, Cantel Medical Corporation, and Meridian Bioscience. Most of the underdeveloped and developing nations lack proper health insurance that covers essential health services. According to a report by the World Bank and the World Health Organization, more than 50% of the world’s population cannot avail of essential health services due to expensive healthcare services that push them to poverty. For instance, 800 million people spend more than 10% of their household budgets on health expenses for themselves, a sick child, or other family members, and for almost 100 million people these expenses are high enough to push them into extreme poverty. This lack of financially affordable healthcare hinders the market growth for diagnostic services including hospital-acquired infection testing. The diagnostic tests involved in diagnosing HAIs such as flow cytometry, mass spectrometry, near-infrared spectroscopy, and nucleic acid-based technologies are advancing in technologies, providing more accurate data. There has been a significant advancement in mass spectrometers, which quantifies known materials, and identifies unknown compounds within a sample. For instance, SCIEX’s X500 QTOF solves the challenge of contamination and is a compact device that does not compromise on resolution and accuracy. It gives results sooner and allows the operator to make data-driven decisions sooner. The hospital-acquired infections testing kits are regulated by government agencies such as US FDA (Food and Drug Administration) in the USA, and the European Medicines Agency/Committee in European Region. The regulatory body lays down a set of guidelines pertaining to the safety, efficiency, and efficacy of the instruments that form part of the hospital-acquired infection testing kits market. The manufacturers and service providers must comply with the CBER Regulations that have been published in the first chapter of Title 21 of CFR. Part 600 of CFR 21 primarily focuses on the established standards like sample retention conditions, temperature to be maintained during shipment, sterilisation of equipment, and the role and duties of the inspector to inspect the laboratories. The regulation also allows the manufacturer to report any kind of deviation of their product from their intended purpose. CBER comes under the FDA (Food and Drug Administration). Also, the Code of Federal Regulations, Title 21, Part 866, states regulations pertaining to immunology and microbiology devices. These devices are used to identify infections caused by bacteria and various viruses. North America was the largest region in the hospital-acquired infections testing kits market in 2022. Western Europe was the second largest region in the global hospital-acquired infections testing kits market share. The regions covered in the global hospital-acquired infections testing kits market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the hospital-acquired infections testing kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The hospital-acquired infections testing kits market consist of sales of testing kits and devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The hospital-acquired infections testing kits market research report is one of a series of new reports from The Business Research Company that provides hospital-acquired infections testing kits market statistics, including hospital-acquired infections testing kits industry global market size, regional shares, competitors with a hospital-acquired infections testing kits market share, detailed hospital-acquired infections testing kits market segments, hospital-acquired infections testing kits market trends and opportunities, and any further data you may need to thrive in the hospital-acquired infections testing kits industry. This hospital-acquired infections testing kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The COVID-19 detection test kits & consumables are used for the identification of novel coronavirus (SARS-CoV-2). This COVID-19 test kits & consumable uses a laboratory procedure called reverse transcription polymerase chain reaction to find the virus' genetic material (RT-PCR). The COVID-19 detection test kits and consumables market covered in this report is segmented by kits into viral load testing kits (qPCR and RT-PCR), virus-neutralizing assay kits, antibody detection kits (ELISA), viral antigen detection test kits, and others. It is also segmented by consumables into swabs, tubes, viral transfer media, reagents, and other consumables and by specimen type into nose and throat swab, blood, sputum, and nasal aspirate. The various end-uses of COVID-19 detection test kits and consumables are hospitals, clinics, public health labs, private and commercial labs, physicians labs, research institutes, and others. The global COVID-19 detection test kits and consumables market is segmented - 1) By Kits: Viral Load Testing Kits (qPCR and RT-PCR), Virus Neutralizing Assay Kits, Antibody Detection Kits (Elisa), Viral Antigen Detection Test Kits, Other Kits 2) By Consumables: Swabs, Tubes, Viral Transfer Media, Reagents, Other Consumables 3) By Specimen Type: Nose & Throat Swab, Blood, Sputum, Nasal Aspirate 4) By End Use: Hospitals, Clinics, Public Health Labs, Private And Commercial Labs, Physicians Labs, Research Institutes, Other End Uses The global covid-19 detection test kits and consumables market size grew from $6.7 billion in 2022 to $7.25 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global covid-19 detection test kits and consumables is expected to grow from $9.83 billion in 2027 at a CAGR of 7.9%. The escalating demand for cost-effective and quick COVID-19 detection kits coupled with the easing of regulatory processes for COVID-19 detection kits contributed to the growth of the COVID-19 detection kits and consumables market. With the increasing incidence of COVID-19 (SARS-CoV-2) worldwide, the outbreak was declared as a Public Health Emergency of International Concern (PHEIC) by WHO. The WHO called for research on point of care diagnostics such as Rapid Diagnostic Tests (RTDs), which are small, simple stand-alone tests for use at the community level, and that can be carried out at the site of triage and outside the hospital, by minimally trained staff, round the clock, and on single samples, providing test results within 15 minutes. In the support of the research, regulatory bodies such as US FDA have eased the COVID-19 detection kits regulatory approval process allowing manufacturers to introduce COVID-19 detection kits in the market on a fast-track basis. Therefore, with the growing number of cases globally and the immense need for rapid diagnosis, the demand for cost-effective and quick COVID-19 detection kits is growing. This factor coupled with ease of the regulatory process for COVID-19 detection kits is driving the covid-19 detection test kits and consumables market. Major players in the COVID-19 detection test kits and consumables market are Cepheid, BGI, Abbott Laboratories, BioFire Diagnostics, F. Hoffmann-La Roche, GenMark Diagnostics, Mylab Discovery Solutions, Qiagen, Quidel Corporation, and Randox Laboratories. Huge demand to increase the capacity combined with a shortage of raw materials used in equipment and a reduced supply of particular reagents and consumables is expected to limit the growth of the COVID-19 detection test kits and consumables market. The pandemic outbreak resulted in lockdown all over the world which has brought shortages of raw materials and halted the supply chain of the particular reagents and consumables for the manufacturing companies as the countries depend on each other for it. For instance, Mpilo lab, the COVID-19 testing laboratory in Bulawayo has stopped conducting tests due to a critical shortage of consumables. Shortages of raw materials due to the disruption in the supply chain coupled with the high pressure to increase the production capacity to meet the demand is likely to harm the profit margins of the COVID-19 detection test kits and consumables market. CRISPR, a new diagnostic test for COVID-19 is based on CRISPR technology and can run on nasal swabs. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) based technologies are genomic editing technologies used for the exact detection of COVID-19 cases in an hour. The US FDA has granted Sherlock Biosciences an emergency use authorization (EUA) for the CRISPR test. The Sherlock Biosciences' CRISPR, therefore becomes the first FDA-authorized CRISPR technology on the market. Mammoth Biosciences is another company that is extensively working on this technology. In April 2020, Co-Diagnostics, a molecular diagnostics company has signed an agreement with Promega for additional manufacturing capacity for the urgent production of its Logix Smart COVID-19 test. Promega will support Co-Diagnostics with its innovative solutions and technical support by providing test kits of its new Logix Smart COVID-19 test to meet the demand during the pandemic. Logix Smart COVID-19 test uses the Co-Primer technology of Co-Diagnostics to target the RdRp gene of the SARS-CoV-2 virus that causes the disease. The test is currently available to all clinical laboratories certified under Clinical Laboratory Improvement Amendments. Promega Corporation will begin supplying complete test kits for further distribution by Co-Diagnostics. The enhanced partnership enables Co-Diagnostics to reach additional testing facilities while leaning on Promega Corporation’s extensive manufacturing capabilities and increased capacity. North America was the largest region in the COVID-19 detection test kits and consumables market in 2022. The regions covered in the COVID-19 detection test kits and consumables market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the COVID-19 detection test kits and consumables market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The COVID-19 detection test kits & consumables market consists of sales of nucleic acid amplification tests (NAATs) and antigen tests. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The COVID-19 detection test kits and consumables market research report is one of a series of new reports from The Business Research Company that provides COVID-19 detection test kits and consumables market statistics, including COVID-19 detection test kits and consumables industry global market size, regional shares, competitors with a COVID-19 detection test kits and consumables market share, detailed COVID-19 detection test kits and consumables market segments, covid-19 detection test kits and consumables market trends and opportunities, and any further data you may need to thrive in the COVID-19 detection test kits and consumables industry. This COVID-19 detection test kits and consumables market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Central lab is a lab that provides bundled services where all of the samples from the trial's clinical locations are submitted. This ensures that the results and analysis are consistent. The main types of services in the central lab are genetic services, biomarker services, microbiology services, anatomic pathology and histology, specimen management and storage, special chemistry services, and others. Genetic services are services that identify and counsel those who are at risk for genetic abnormalities. The different test types include human and tumor genetics, clinical chemistry, medical microbiology and cytology, and other esoteric tests that are employed in several end-users such as pharmaceutical companies, academic and research institutes, and biotechnology companies. The global central lab market is segmented - 1) By Service Type: Genetic Services, Biomarker Services, Microbiology Services, Anatomic Pathology or Histology, Specimen Management And Storage, Special Chemistry Services, Other Service Types 2) By Test Type: Human And Tumor Genetics, Clinical Chemistry, Medical Microbiology And Cytology, Other Esoteric Tests 3) By End-User: Pharmaceutical Companies, Academic And Research Institutes, Biotechnology Companies The global central lab market size grew from $2.52 billion in 2022 to $2.74 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global central lab is expected to grow to $3.64 billion in 2027 at a CAGR of 7.3%. The rise in the number of clinical trials is expected to drive the central lab market going forward. A clinical trial is a type of research study that is aimed at evaluating a new treatment, a new drug, or a medical device’s safety and effectiveness. Pharmaceutical and biotechnology companies outsource central labs for testing, development, and production of new products. For instance, according to ClinicalTrials.gov, a registry of clinical trials by the National Library of Medicine and a US-based medical library operated by the US federal government, as of July 2022, 422,646 clinical trials were listed as compared to 399,523 in 2021. Therefore, the rise in the number of clinical trials will promote the central lab market. Major players in the central lab market are Acm Global Laboratories Private Limited, Cerba Research, Sonic Healthcare Limited, Celerion Inc., Cirion Biopharma Research Inc., Clinical Reference Laboratory Inc., Eurofins Central Laboratory LLC, Frontage Laboratories Inc., Icon Central Labs, Interlab Central Lab Services, InVitro International, Labcorp Drug Development India Private Limited, LabConnect LLC, Medpace Clinical Research India Private Limited, MLM Medical Labs GmbH, Synevo Central Lab, and Q2 Solutions Pty Ltd. Technological advancements are a key trend gaining popularity in the central lab market. Major companies operating in the central lab sector are focused on developing new technological solutions to strengthen their position in the market. For example, in December 2021, Instron, a US-based manufacturer of a wide range of cutting-edge materials testing equipment, introduced BluehillCentral Lab management software that allows lab administrators to remotely use Bluehill Central Lab regardless of the quantity or location of test systems. The new Bluehill Central software streamlines the lab administration procedure by managing Instron systems and data at the enterprise level using a single database. With this platform, lab administrators can remotely manage a variety of operations across all the frames on their network, including all Bluehill Universal users and permissions, test method templates, results, file revision approvals, and audit trail information. In December 2021, Thermo Fisher Scientific, a US-based supplier of scientific instrumentation, reagents and consumables, and software services, acquired PPD Inc. for $17.4 billion. The acquisition is expected to strengthen Thermo Fisher's capabilities and help it become an industry leader in clinical research services. PPD, Inc. (Pharmaceutical Product Development), is a US-based contract research organization providing comprehensive, integrated drug development, laboratory, and lifecycle management services. North America was the largest region in the central lab market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central lab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the central lab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The central lab market includes revenues earned by entities by providing services such as specimen management, kit and logistics, and clinical trial data analytics services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The central lab market research report is one of a series of new reports from The Business Research Company that provides central lab market statistics, including central lab industry global market size, regional shares, competitors with a central lab market share, detailed central lab market segments, market trends and opportunities, and any further data you may need to thrive in the central lab industry. This central lab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

An architectural firm provides services such as planning, designing, and supervising the complex task of building construction. An engineering firm can provide extensive consultation to a company needing expert advice and solutions. The company can accept the project and work on evaluating, designing, simulating, and testing the product. The main types of architectural and engineering consultants and related services are engineering services, architectural services, surveying and mapping services, geophysical services, laboratory testing services, building inspection services, and drafting services. Engineering services are defined as those provided for system, assembly, or product deployments that are comparable in material, design, and scope to those stated for this program. It is used in various applications such as road, rail, port, airport, pipeline, power and others. The different service providers include large enterprises as well as small and medium-sized enterprises. The global architectural, engineering consultants and related services market is segmented - 1) By Type: Engineering Services, Architectural Services, Surveying & Mapping Services, Geophysical Services, Laboratory Testing Services, Building Inspection Services, Drafting Services 2) By Application: Road, Rail, Port, Airport, Pipeline, Power, Other Applications 3) By Service Provider: Large Enterprise, Small and Medium Enterprise Subsegments Covered: Civil Engineering Services, Electrical Engineering Services, Mechanical Engineering Services, Other Engineering Services, Landscape Architectural Services, Building And Structural Architectural Services Geophysical Data Collection, Geophysical Data Sales, Integrated Geophysical Services, Other Geophysical Services The global architectural, engineering consultants and related services market grew from $1,456.69 billion in 2022 to $1,525.79 billion in 2023 at a compound annual growth rate (CAGR) of 4.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The market size of global architectural, engineering consultants and related services market is expected to grow from $1,773.06 billion in 2027 at a CAGR of 3.8%. The rise in demand for environmentally safe and certified buildings is expected to drive the architecture and engineering services market. Consumers, state governments, and NGOs are working towards making residential and commercial buildings more energy efficient and self-sufficient. Private constructors and real estate developers are redesigning projects to fulfil these demands, leading to many benefits such as an increase in rental and resale value, home-owner satisfaction, lower operating costs, and regional or international recognition. The US Green Building Council launched the Leadership in Energy and Environmental Design (LEED) certification program to establish a set of rating systems that define the construction, design, and maintenance of residential projects. According to a study by the US Green Building Council (USGBC), LEED-certified buildings have managed to reduce carbon, energy, waste, and water waste by almost 30–97% and operating costs by more than 9%. Major companies in the architecture, engineering, and other related services market include PowerChina, Fluor Corporation, AECOM Technology Corporation, WorleyParsons Limited, McDermott International Inc., Jacobs Engineering Group Inc., John Wood Group PLC, KBR Inc., Babcock International, and WSP Global Inc. The outbreak of COVID-19 disease (COVID-19) has acted as a restraint on the architectural, engineering, and related services market in 2020 as governments globally imposed lockdowns and restricted trade, thereby limiting the need for professional services. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China and has spread globally, including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of "lock down." The outbreak has had a negative impact on businesses throughout 2020 and into 2021. However, it is expected that the architectural, engineering, and related services market will recover from the shock across the forecast period as it is a 'black swan' event and not related to ongoing or fundamental weaknesses in the market or the global economy. Architectural and engineering consultants are using 5D building information modelling (BIM) to create dynamic building designs that can be altered at later stages of the project. BIM software is a tool used to design buildings and structures, including lighting, HVAC systems, and mechanical, electrical, and plumbing systems. It can also be used for clash detection, cost estimation, and safety analysis. 5D building information modelling (BIM) involves creating architectural designs that can be modified and customized in real time. This system collects data from different project teams and helps collaborate with the entire construction chain, eliminating project delays. For instance, construction management company The Korte Company is using 5D BIM technology for project design, planning, and cost estimation, thereby enabling faster decision-making. The Maharashtra Metro Rail Corporation in the Indian state of Maharashtra is using 5D BIM in its construction projects worth $3 billion to reduce costs and litigation. Western Europe was the largest region in the architectural, engineering consultants and related services market share in 2022. North America was the second largest region in the architectural, engineering consultants and related services market. The regions covered in the global architecture, engineering consultants and other related services (A, EC & related services) market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the architectural, engineering consultants and related services market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The architecture, engineering and other related services market consists of revenue earned by entities by providing support to the planning and designing of construction related businesses of all sizes across all industries. Business entities that are engaged in providing architecture, engineering and other related services are generally referred to as architectural firms or engineering consultancy firms. Architecture, engineering and related services undertake processes where human capital is the major input. They make available the knowledge and skills of their employees, often on an assignment basis, where an individual or team is responsible for the delivery of services to the client. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global architectural, engineering, and related services market research report is one of a series of new reports from The Business Research Company that provides global architectural, engineering, and related services market statistics, including global architectural, engineering, and related services industry global market size, regional shares, competitors with a global architectural, engineering, and related services market share, detailed global architectural, engineering, and related services market segments, market trends and opportunities, and any further data you may need to thrive in the global architectural, engineering, and related services industry. This global architectural, engineering, and related services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal diseases drug categories include Anti-peptic agents (antacids, antagonists, Proton Pump Inhibitors, Sucralfate, and Misoprostol), antiemetics, adsorbents, anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants, hyperosmotic, saline, and simulant/irritant. The main types of gastrointestinal drugs are antacids, antiulcerants, vitamin and minerals, antiobesity, antiemetics and antinauseants and antidiarrhoeals. Antacids are medications that counteract (neutralise) stomach acid to relieve indigestion and heartburn. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global gastrointestinal drugs market size is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%. The change in the gastrointestinal drugs market growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The gastrointestinal drugs market is expected to reach $105.51 billion in 2026 at a CAGR of 8.7%. The aging population profile of most countries will contribute to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, will contribute significantly to the growth of the market during the forecast period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This will led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. During the forecast period, the growth of the gastrointestinal drugs market will be restrained by patent expiration of branded gastrointestinal drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this will negatively impact the growth of the market in terms of value. Major companies in the gastrointestinal drug industry are investing in making oral capsules of macromolecular drugs for gastrointestinal diseases for making the drug more effective. Macromolecular drugs, such as peptides, proteins, and antibodies, form a new class of drugs which can treat diseases of the gastrointestinal tract, such as inflammatory bowel disease. These macromolecular drugs are usually injected and only a fraction of the administered dose reaches the disease sites in the gastrointestinal tract. Thus, major companies such as Eli Lilly have been increasingly investing in making oral capsules for macromolecular drugs. The company invested $5 million to enter into a collaboration with Entrega to study the oral delivery of complex molecules, such as peptides to combat gastrointestinal diseases. Major companies in the gastrointestinal drugs market include Takeda Pharmaceuticals, Bayer AG, Abbott Laboratories, Otsuka Holdings Co ltd, Johnson & Johnson, Reckitt Benckiser Group plc, Bausch Health Companies Inc., Sanofi S.A, Procter & Gamble and Daiichi Sankyo Company. North America was the largest region in the gastrointestinal drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the gastrointestinal drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastrointestinal drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global gastrointestinal drugs market is segmented - 1) By Type: Antacids, Antiulcerants, Vitamin and Minerals, Antiobesity, Antiemetics and Antinauseants, Antidiarrhoeals 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

Pharmaceutical Drugs And Biologics Logistics Market Definition

The pharmaceutical drugs and biologics market consists of sales of pharmaceutical drugs and biologics logistics services by entities (organizations, sole traders and partnerships) that provide pharmaceutical drugs and biologics logistics services. Pharmaceutical drugs and biologics logistics is the logistics of pharmaceutical and biologic drugs from the manufacturer to the end-user. It includes transportation, warehousing, inventory management and other logistics functions.